English
Home > Products > Bepotastine API

China Bepotastine API Factory

We also offer you product sourcing and flight consolidation expert services. We've our personal manufacturing unit and sourcing business. We can offer you virtually every variety of merchandise associated to our item range for Bepotastine API,CAS NO 190786-44-8,190786-44-8,Bepotastine Besilate, Never-ending improvement and striving for 0% deficiency are our two main quality policies. Should you need anything, don't hesitate to contact us.
Bepotastine API, We believe in establishing healthy customer relationships and positive interaction for business. Close cooperation with our customers has helped us to create strong supply chains and reap benefits. Our products have gained us widespread acceptance and the satisfaction of our worldwide valued clients.

Related Products

Hot Products

  • BOC-Glycine

    BOC-Glycine

    Product Name:BOC-Glycine
    Molecular Formula:C7H13NO4
    Molecular Weight:175.18
    CAS Registry Number:4530-20-5
  • 1,2-Diaminocyclohexane

    1,2-Diaminocyclohexane

    Product Name:1,2-Diaminocyclohexane
    Molecular Formula:C6H14N2
    Molecular Weight:114.19
    CAS Registry Number:694-83-7
  • Adenosine 5’-monophosphate, free acid

    Adenosine 5’-monophosphate, free acid

    Product Name:Adenosine 5’-monophosphate, free acid
    Molecular Formula:C10H14N5O7P
    Molecular Weight:347.22
    CAS Registry Number:61-19-8
  • Pidotimod

    Pidotimod

    Product Name:Pidotimod
    Molecular Weight:244.27
    CAS Registry Number:121808-62-6
  • L-Glutamine

    L-Glutamine

    Product Name:L-Glutamine
    Molecular Formula:C5H10N2O3
    Molecular Weight;146.14
    CAS Registry Number;56-85-9
  • 1,1,1,2,2,3,3,4,4,5,5,6,6-Tridecafluoro-8-iodooctane

    1,1,1,2,2,3,3,4,4,5,5,6,6-Tridecafluoro-8-iodooctane

    Product Name:1,1,1,2,2,3,3,4,4,5,5,6,6-Tridecafluoro-8-iodooctane
    Molecular Formula:C8H4F13I
    Molecular Weight:474.0
    CAS Registry Number:2043-57-4
  • Related Blog
  • Reviews

  • Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

    Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products...

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications.

  • Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

    Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products can be produced in ordinary chemical plants without obtaining a pharmaceutical production license. As long as the technical indicators meet certain level requirements, they can be used to participate in the synthesis and production of drugs.

  • Development Trend of China's Pharmaceutical Intermediate Industry

    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.

  • Gilteritinib Fumarate

    Sandoo Pharmaceutica is a professional pharmaceutical intermediates manufacturer. We provide good quality Gilteritinib Fumarate Cas: 1254053-43-4. Welcome and we look forward to your inquiry!

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept